Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.72 |
| ▸ | MAOB | P27338 | 5/20 | 0.72 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2561325 | 1.00 | MAOA (0.72) | MAOAMAOBACHEBCHEADRA2B | |
| SCHEMBL13930053 | 1.00 | MAOA (0.72) | MAOAMAOBACHEBCHEADRA2B | |
| SCHEMBL13154525 | 0.90 | MAOA (0.63) | MAOAMAOBACHEBCHEADRA2B | |
| SCHEMBL2474759 | 0.90 | MAOA (0.63) | MAOAMAOBACHEBCHEADRA2B | |
| Cadaverine Tartrate SCHEMBL5453486 | 0.87 | MAOA (0.56) | MAOAMAOBACHEBCHEADRA2B | |
| SCHEMBL23125436 | 0.84 | MAOA (0.68) | MAOAMAOBACHEBCHEADRA2B | |
| SCHEMBL5443706 | 0.84 | MAOA (1.00) | MAOAMAOBACHEBCHEADRA2B | |
| SCHEMBL4348709 | 0.84 | MAOA (0.68) | MAOAMAOBACHEBCHEADRA2B | |
| SCHEMBL23125472 | 0.84 | MAOA (0.68) | MAOAMAOBACHEBCHEADRA2B | |
| SCHEMBL14527007 | 0.84 | MAOA (0.68) | MAOAMAOBACHEBCHEADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1954667-B1 | METHODS FOR ISOLATING PROPARGYLATED AMINOINDANS | TEVA PHARMA (IL) | 2017-02-08 | — | — | EP | disclosed |
| EP-2657221-A1 | Preparation of rasagiline and salts thereof | Dr. Reddy's Laboratories Ltd. (IN) | 2013-10-30 | — | — | EP | disclosed |
| US-20110218360-A1 | PREPARATION OF RASAGILINE AND SALTS THEREOF | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-09-08 | — | — | US | disclosed |
| US-20110218360-A1 | PREPARATION OF RASAGILINE AND SALTS THEREOF | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-09-08 | — | — | US | disclosed |
| US-20110218360-A1 | PREPARATION OF RASAGILINE AND SALTS THEREOF | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-09-08 | — | — | US | disclosed |
| EP-2358658-A2 | PREPARATION OF RASAGILINE AND SALTS THEREOF | Dr. Reddy's Laboratories, Ltd. (IN) | 2011-08-24 | — | — | EP | disclosed |
| WO-2011048612-A2 | PROCESSES FOR THE PREPARATION OF PROPARGYLATED AMINOINDANS OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | GLENMARK GENERICS LIMITED (IN) | 2011-04-28 | — | — | WO | disclosed |
| WO-2010059913-A2 | PREPARATION OF RASAGILINE AND SALTS THEREOF | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010059913-A2 | PREPARATION OF RASAGILINE AND SALTS THEREOF | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-05-27 | — | — | WO | disclosed |
| US-7491847-B2 | Methods for isolating propargylated aminoindans | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2009-02-17 | — | — | US | disclosed |
| US-7491847-B2 | Methods for isolating propargylated aminoindans | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2009-02-17 | — | — | US | disclosed |
| WO-2007061717-A2 | METHODS FOR ISOLATING PROPARGYLATED AMINOINDANS | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2007-05-31 | — | — | WO | disclosed |
| US-20070112217-A1 | Methods for isolating propargylated aminoindans | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112217-A1 | Methods for isolating propargylated aminoindans | AAAS, AGT, ARL1 | MAOA 1000/4885MAOB 1418/4885ACHE 1083/4885 |
| US-20110218360-A1 | PREPARATION OF RASAGILINE AND SALTS THEREOF | RAB35, RAB27A, RAB5C | MAOA 336/4885MAOB 423/4885ACHE 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.